HIGHLIGHTS
- who: Binghe Xu from the (UNIVERSITY) have published the research: Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study, in the Journal: (JOURNAL)
- what: The authors report the safety and efficacy of pamiparib in a phase II, multicenter study in Chinese patients with locally advanced or metastatic HER2- breast cancer harboring germline BRCA1/2 mutations (gBRCA1/2 m). This study was designed to provide adequate power to test the hypothesis for the primary endpoint of ORR by IRC in the efficacy evaluable TNBC cohort . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.